Sign up to save your podcasts
Or
Share The Glucose Sensor That Predicts the Future with Mark Tapsak
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Glucose Sensor That Predicts the Future with Mark Tapsak
In this episode, Henry Norton sits down with Mark Tapsak, Chief Science Officer at Glucotrack and one of Dexcom's earliest employees.
Mark Tapsak left Medtronic for a "crazy startup" called Dexcom after seeing data so compelling he couldn't say no. Two decades later, he's back in the CGM game as Chief Science Officer at Glucotrack, working on a 3-year implantable sensor that lives in the bloodstream.
Key Topics:
Mark's path from blue-collar Minnesota to polymer chemistry PhD
The founding days of Dexcom and the "three fathers" of CGM (Goff, Updike, Heller)
Why early CGM struggled to convince endocrinologists of continuous data's value
Dexcom's pivot from implantable to short-term sensors
Glucotrack's evolution from non-invasive ear clip to intravascular 3-year sensor
Current trial progress in Brazil and Australia, and the path to US IDE
Related Insights:
Why implanting devices in the body is "harder than going to the moon"
The business case for long-term implantables vs. wearables
How the immune response creates a "sleep period" that tanks glucose signals
Why timing and market readiness matter as much as technology
Core Challenges:
Early CGM implantables worked in only ~50% of patients, forcing a pivot to wearables and delaying long-term solutions by decades.
Glucotrack is now targeting a 3-year intravascular sensor that bypasses the aggressive subcutaneous immune response, with US trials expected in 2026.
🎧 Tune in now to hear how CGM went from academic curiosity to medical device success story, and what comes next.
The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.
To learn more about Cruxx, click here.
A big thank you to our sponsors on this season of the podcast;
TTP plc With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, TTP plc can accelerate your development with the latest technologies. Learn more at TTP.com
View all episodes
By The Crux of Medtech
5
22 ratings
In this episode, Henry Norton sits down with Mark Tapsak, Chief Science Officer at Glucotrack and one of Dexcom's earliest employees.
Mark Tapsak left Medtronic for a "crazy startup" called Dexcom after seeing data so compelling he couldn't say no. Two decades later, he's back in the CGM game as Chief Science Officer at Glucotrack, working on a 3-year implantable sensor that lives in the bloodstream.
Key Topics:
Mark's path from blue-collar Minnesota to polymer chemistry PhD
The founding days of Dexcom and the "three fathers" of CGM (Goff, Updike, Heller)
Why early CGM struggled to convince endocrinologists of continuous data's value
Dexcom's pivot from implantable to short-term sensors
Glucotrack's evolution from non-invasive ear clip to intravascular 3-year sensor
Current trial progress in Brazil and Australia, and the path to US IDE
Related Insights:
Why implanting devices in the body is "harder than going to the moon"
The business case for long-term implantables vs. wearables
How the immune response creates a "sleep period" that tanks glucose signals
Why timing and market readiness matter as much as technology
Core Challenges:
Early CGM implantables worked in only ~50% of patients, forcing a pivot to wearables and delaying long-term solutions by decades.
Glucotrack is now targeting a 3-year intravascular sensor that bypasses the aggressive subcutaneous immune response, with US trials expected in 2026.
🎧 Tune in now to hear how CGM went from academic curiosity to medical device success story, and what comes next.
The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency.
To learn more about Cruxx, click here.
A big thank you to our sponsors on this season of the podcast;
TTP plc With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, TTP plc can accelerate your development with the latest technologies. Learn more at TTP.com